Dr. Chad Lewis oversees the production of all K36 pharmaceutical agents.

 

Prior to joining K36, Dr. Lewis was the Associate Director of Chemistry at FogPharma where he managed the chemistry group for stapled peptide synthesis and development. Chad also served as a Senior Principal Scientist at Pfizer and led a multidisciplinary team for the multi-ton process chemistry development of the JAK1 inhibitor, Abrocitinib (CIBINQO), for the treatment of atopic dermatitis. Prior to Pfizer, he was an Assistant Professor of Chemistry at Cornell University where he researched the synthesis of rare marine toxin alkaloids and carbasugar synthetic methods.

​

Dr. Lewis earned his B.Sc. in Chemistry with Honors at the University of Alberta, a Ph.D. in Chemistry at Yale University, a Postdoctoral Fellow at The Scripps Research Institute, and an MBA from Marist College. He has authored a book chapter, several patents, and co-authored more than 20 academic publications ranging from new synthetic methods to organocatalysis.